Press

Bright Green Embarks on Major Partnership With Benuvia Pharmaceuticals Will Supply Pharma Expert With American Made Raw Materials From Its Industry Leading and DEA-Approved SCH I & II Drug Facility

Aug 22 • 3 min read

GRANTS, NEW MEXICO, Aug. 21, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently…

MindBio Therapeutics Corp. Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials

Aug 20 • 4 min read

MindBio Therapeutics Corp. reported durability data from Phase 2A clinical trials in depressed patients testing MB22001, MindBio’s proprietary self-administered take home microdose of Lysergic Acid Diethylamide (LSD). The Phase 2a clinical trial demonstrated excellent safety, adherence and tolerance profile in doses tested. This was consistent with the Phase 1 trial results and the findings augment…

PharmaDrug’s Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine

Aug 20 • 3 min read

Toronto, Ontario–(Newsfile Corp. – August 19, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that on the 12th of August 2024, Sairiyo Therapeutics…

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

Aug 20 • 3 min read

Vancouver, Canada – Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (‘Clearmind’ or the ‘company’), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (‘PCT’) as part of the company’s ongoing collaboration with the with Yissum Research…

Hempacco Co., Inc. Announces Board and Committee Appointments

Aug 16 • 3 min read

On August 9, 2024, the Board of Directors of Hempacco Co., Inc. appointed Paul Glavine and Harrison Newlands as members of the Board of the Company to fill two vacancies on the Board. Mr. Glavine and Mr. Newlands are both considered ?independent? directors under relevant SEC and Nasdaq rules, and they will each serve with…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435